The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients, ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE:BMY) in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback